BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ActiveSight Release: Fructose-1,6-bisphosphatase Diabetes Target Available For Structure Based Drug Design


10/19/2005 5:12:34 PM

SAN DIEGO, Jan. 27 /PRNewswire/ -- Fructose-1,6-bisphosphatase (FBPase) is a key regulatory enzyme in the gluconeogenic pathway and a target for the development of novel diabetes therapeutics focused on lowering hepatic glucose production in type 2 diabetics. By offering co-crystallization structure services for this target, ActiveSight is making it possible for client companies to easily apply the principles of rational structure-based design to their proprietary lead compounds.

"FBPase is the first of a suite of important diabetes target proteins we will be introducing this year," stated Les Tari, PhD, ActiveSight's Director of Structural Biology. "Our goal is to accelerate our customers' drug development programs by putting key structural information within their reach."

ActiveSight is building a portfolio of "Ready-to-Go" key drug targets. Human FBPase is the second target to be introduced. The first portfolio protein was human Hsp90, an emerging oncology target.

About ActiveSight

ActiveSight(TM), a structural biology company in San Diego, California, provides outsourcing solutions to the pharmaceutical and biotechnology industries. ActiveSight is a division of Rigaku/MSC. Visit us at http://www.active-sight.com/.

ActiveSight

CONTACT: Joy Silen of ActiveSight, +1-858-455-6870, ext. 105



Read at BioSpace.com

   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES